Larimar Therapeutics, Inc. (LRMR)

6.65 +0.13 (+1.99%) At close: 04:00PM EDT

Larimar Therapeutics, Inc.

Three Bala Plaza East
Suite 506
Bala Cynwyd, PA 19004
United States
844 511 9056
https://www.larimartx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 42

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Carole S. Ben-Maimon M.D.	CEO, President & Director	865k	N/A	1959
Mr. Michael Celano CPA	Secretary & CFO	577.58k	N/A	1959
Dr. Gopi Shankar M.B.A., Ph.D.	Chief Development Officer	593.02k	N/A	1971
Mr. John Berman	Vice President of Finance & Administration	N/A	N/A	N/A
Ms. Jennifer Spokes Johansson	Vice President of Legal & Compliance	N/A	N/A	N/A
Dr. Russell G. Clayton Sr., D.O, D.O.	Chief Medical Officer	N/A	N/A	1961
Mr. Francis Michael Conway CPA	VP & Controller	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Corporate governance

Larimar Therapeutics, Inc.’s ISS governance QualityScore as of 1 October 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.